Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477146 | 0.78 | KDM1A (0.34) | MAPTHTT | |
| SCHEMBL4983556 | 0.78 | KDM1A (0.34) | MAPTHTT | |
| SCHEMBL707400 | 0.76 | CA1 (0.33) | DDB1CRBNCA1CA2MAOB | |
| SCHEMBL707705 | 0.76 | CA1 (0.33) | DDB1CRBNCA1CA2MAOB | |
| SCHEMBL14796754 | 0.74 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL2508886 | 0.65 | GAA (0.37) | DDB1CRBNCA1CA2MAOB | |
| SCHEMBL15768826 | 0.60 | HDAC4 (0.44) | CA1CA2HTTHDAC4ALDH1A1 | |
| SCHEMBL12499379 | 0.60 | HDAC4 (0.44) | CA1CA2HTTHDAC4ALDH1A1 | |
| SCHEMBL11215167 | 0.59 | DDB1 (0.47) | DDB1CRBNKDM4EALDH1A1HSD17B10 | |
| SCHEMBL13688280 | 0.57 | FFAR3 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124633-B2 | Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | DDB1 1892/4885CRBN 4350/4885CA1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.